How much does prophylaxis actually reduce bleeding?
The short answer: a lot. In the largest prospective study here (WIL-31), which included children as young as 6 years old, switching from on-demand treatment to regular prophylaxis with a plasma-derived VWF/factor VIII concentrate reduced the mean total annualized bleeding rate by 84%—from about 33 bleeds per year to about 5 [2]. That means a child who was bleeding roughly every 11 days on demand would bleed about once every 10 weeks on prophylaxis. The reduction was consistent across age groups and VWD types, and nearly half of patients had zero spontaneous bleeds during the year of prophylaxis [2][8].
A separate phase 3 trial of recombinant VWF in adults (with some pediatric data) found an even larger drop: treated spontaneous bleeding fell by 91.5% in patients who had previously used on-demand therapy, and 85% of those patients had no treated spontaneous bleeds at all during the year [7]. Real-world data from a phase 4 study of 111 patients (including 41 children) showed a median annualized bleeding rate of just 1.9 during prophylaxis—meaning most patients had fewer than two bleeds per year [9]. Across these studies, the message is consistent: prophylaxis is highly effective at preventing bleeds in VWD.
Does starting early prevent complications before they pile up?
The evidence suggests yes, but it's indirect. The rationale is that prophylaxis prevents bleeds, and bleeds cause complications. For example, in a pediatric cohort of infants and toddlers with VWD, 70% had a bleeding event before age 2, with oral bleeding, circumcision-related bleeding, and even intracranial hemorrhage (5% of the cohort) occurring early [6]. Starting prophylaxis early could prevent these events and their downstream effects, such as iron deficiency anemia from heavy menstrual bleeding or joint damage from recurrent joint bleeds (though joint bleeds are less common in VWD than in hemophilia).
Heavy menstrual bleeding is a major complication in girls and women with VWD, affecting up to 80–90% of them. In the WIL-31 study, prophylaxis reduced the heavy menstrual bleeding rate by 64% compared with on-demand treatment, and the proportion of women experiencing any heavy menstrual bleeding dropped from 86% to 29% [3]. This is crucial because heavy menstrual bleeding often leads to iron deficiency anemia, emergency visits, and even hysterectomy—complications that prophylaxis could prevent if started early [4]. However, a real-world study in women found that VWF prophylaxis was underused (only 8% of women with heavy menstrual bleeding received it), and the authors called for earlier prophylaxis to prevent complications [4].
When is prophylaxis worth it—and when is it overkill?
Prophylaxis is clearly beneficial for children with severe VWD (types 2 and 3) who have frequent, severe bleeds. In WIL-31, the majority of patients had type 3 VWD, and the benefit was consistent across types [2][8]. A dedicated pediatric study of recombinant VWF prophylaxis is currently underway, but existing data support its use in children with severe disease [10]. For these children, the reduction in bleeding—and the prevention of complications like nosebleeds (reduced by 76% in WIL-31) and heavy menstrual bleeding—justifies the burden of regular infusions [5][3].
For children with mild type 1 VWD (VWF levels 30–50 IU/dL), the picture is different. A 2024 retrospective study of 108 children with mild type 1 VWD found that most procedures could be managed safely with just antifibrinolytics (like tranexamic acid), and bleeding complications occurred in only 5% of procedures—and none required transfusion or additional surgery [1]. This suggests that for mild cases, a tailored, on-demand approach may be sufficient, and prophylaxis might be unnecessary. The decision should be individualized, based on the child's bleeding history, not just the VWD type. As one study noted, guidelines conditionally recommend prophylaxis for those with severe and frequent bleeds, but the evidence for mild cases is less certain [2][7].
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2021 to 2024, 3 from 2024 or later, 7 in Q1 journals, collectively cited 71 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 49 papers retrieved from a database of over 500 million.
Sources used in this answer
Procedural outcomes in children with mild type 1 von Willebrand disease
In a retrospective cohort of 108 children with mild type 1 VWD undergoing 161 procedures, bleeding complications occurred in only 5% of procedures, and most were managed with antifibrinolytics alone, suggesting tailored on-demand management is safe for mild cases.
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease
In the prospective WIL-31 trial of 33 patients (including children ≥6 years) with severe VWD, prophylaxis with Wilate reduced mean total annualized bleeding rate by 84% compared with on-demand treatment, with consistent benefit across age and VWD types.
Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Heavy Menstrual Bleeding in Females with Von Willebrand Disease
In a subanalysis of WIL-31, prophylaxis reduced heavy menstrual bleeding rate by 64% compared with on-demand treatment, and the proportion of women with any heavy menstrual bleeding dropped from 86% to 29%.
Rates and Predictors of Prophylaxis in Women with Von Willebrand Disease and Heavy Menstrual Bleeding
A retrospective study of 168 women with VWD found that only 8% used VWF prophylaxis despite high rates of heavy menstrual bleeding and iron deficiency anemia, and prophylaxis use was not associated with reduced severe HMB, possibly due to confounding by indication.
Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease
In a post-hoc analysis of WIL-31, prophylaxis reduced nosebleed rate by 76% compared with on-demand treatment, with consistent reductions across age groups and the greatest benefit in types 2 and 3 VWD.
Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD
In a US cohort of 105 infants and toddlers with VWD, 70% had a bleeding event before age 2, with oral bleeding, circumcision-related bleeding, and intracranial hemorrhage being common, highlighting the need for early management.
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
In a phase 3 trial of recombinant VWF prophylaxis in adults with severe VWD, treated spontaneous bleeding rate decreased by 91.5% in patients switching from on-demand therapy, and 85% had no treated spontaneous bleeds.
PB0841 Investigation of VWD in Women with Menorrhagia or Dysmenorrhea Associated with Bleeding
In the WIL-31 trial, prophylaxis with pdVWF/FVIII reduced median treated total ABR from 22.4 to 1.0 in the overall population, and from 24.8 to 1.0 in type 3 patients, with 55% of patients having zero treated spontaneous bleeds.
Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease
A real-world phase 4 study of 111 patients (including 41 children) found that prophylaxis with Wilate resulted in a median annualized bleeding rate of 1.9, with excellent tolerability and no unexpected adverse events.
A Phase 3, Prospective, Open-Label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease
A phase 3 trial of recombinant VWF prophylaxis in children with severe VWD is ongoing, aiming to evaluate efficacy and safety in up to 24 pediatric participants across three age ranges.